varenicline + hydroxyzine

Varenicline + hydroxyzine is a combination of two pharmaceutical agents: varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptors indicated primarily for smoking cessation, and hydroxyzine, a first-generation antihistamine with sedative and anxiolytic properties. This combination has been studied in an open-label trial for potential synergistic effects in smoking cessation, specifically to reduce common side effects of varenicline such as nausea, stress, anxiety, and sleep disturbances, and to improve overall tolerability and compliance during nicotine withdrawal. Varenicline acts centrally to reduce cravings and withdrawal symptoms via dopaminergic pathways, while hydroxyzine acts as an antagonist at histamine H1 receptors and other neurotransmitter systems, producing sedation and anxiolysis[2][5][4].